Veloxis Pharmaceuticals AS (VELO) – Financial and Strategic SWOT Analysis Review

Date: 2015-12

“Veloxis Pharmaceuticals AS (VELO) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

– Business description – A detailed description of the company’s operations and business divisions.
– Corporate strategy – Analyst’s summarization of the company’s business strategy.
– SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
– Company history – Progression of key events associated with the company.
– Major products and services – A list of major products, services and brands of the company.
– Key competitors – A list of key competitors to the company.
– Key employees – A list of the key executives of the company.
– Executive biographies – A brief summary of the executives’ employment history.
– Key operational heads – A list of personnel heading key departments/functions.
– Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
– Key manufacturing facilities – A list of key manufacturing facilities of the company.
– Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
– Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.


Veloxis Pharmaceuticals A/S (Veloxis), formerly LifeCycle Pharma A/S, is a specialty pharmaceutical company, which develops therapies based on its proprietary MeltDose reformulation technology platform. The company’s products are mainly used for cardiovascular indications and transplant immunosuppression. Veloxis’s product portfolio includes Envarsus, LCP-AtorFen and Fenoglide. LCP-FenoChol helps in the treatment of mixed dyslipidemia, hypertriglyceridemia and hypercholesterolemia and is sold under the brand name Fenoglide in the US. Envarsus is a once-daily dosage, primary immunosuppressant in the transplant market. Envarsus is sold in Europe for prophylaxis of organ rejection in adult kidney and liver transplant patients in Europe. The company has a wholly owned subsidiary, Veloxis Pharmaceuticals Inc., in New Jersey, the US. Veloxis is headquartered in Horsholm, Denmark.

Veloxis Pharmaceuticals AS Key Recent Developments

Aug 26, 2015: Veloxis Pharmaceuticals announces financial results for the first six months of 2015 and improves the full year outlook
May 20, 2015: Veloxis Pharmaceuticals announces financial results for the first three months of 2015
Mar 03, 2015: Veloxis Pharmaceuticals publishes Annual Report 2014
Nov 13, 2013: Veloxis Pharmaceuticals announces financial results for the first nine months of 2013 and improves the full year outlook
Aug 21, 2013: Veloxis Pharmaceuticals announces financial results for the first half 2013

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
– The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
– The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
– Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
– Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
– Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company”

Contact With Us
Join templatemonster at google+
Customized Research
Request Sample